Abstract：
OBJECTIVE: To investigate the clinicopathological features, prognostic factors, treatment, clinical response, and outcome of gestational choriocarcinoma (GCC).
METHODS: A retrospective review was made of the clinicopathological and survival data of 13 patients who were diagnosed and treated for GCC in two referral centers in Turkey between 1992 and 2020.
RESULTS: The median age of patients was 36 years (range, 27-54 years), and seven were ≤39 years. The antecedent pregnancy was a term in nine (69.2%) cases, and the risk score was ≥7 in 11 (84.6%). According to the International Federation of Gynecology and Obstetrics 2009 staging, eight cases were in stage I, two in stage III, and three in stage IV. With the exception of one patient, all the others received combination chemotherapy (CT), and two of those were also treated with radiotherapy. Chemoresistance developed in 50% (6/12), and second-line CT was given to four of these. The overall complete response rate was 69.2%. Four patients died of chemoresistance and disease progression, all of them were with antecedent-term pregnancy, had high scores ≥7, and had metastases.
CONCLUSIONS: GCC is a unique subtype of gestational trophoblastic neoplasia, which differs from others in terms of poor prognosis, a frequent tendency to early metastasis, and resistance to treatment. To be able to achieve the most efficient therapy and prognosis, histopathology-based risk models should be developed.
METHODS: A retrospective review was made of the clinicopathological and survival data of 13 patients who were diagnosed and treated for GCC in two referral centers in Turkey between 1992 and 2020.
RESULTS: The median age of patients was 36 years (range, 27-54 years), and seven were ≤39 years. The antecedent pregnancy was a term in nine (69.2%) cases, and the risk score was ≥7 in 11 (84.6%). According to the International Federation of Gynecology and Obstetrics 2009 staging, eight cases were in stage I, two in stage III, and three in stage IV. With the exception of one patient, all the others received combination chemotherapy (CT), and two of those were also treated with radiotherapy. Chemoresistance developed in 50% (6/12), and second-line CT was given to four of these. The overall complete response rate was 69.2%. Four patients died of chemoresistance and disease progression, all of them were with antecedent-term pregnancy, had high scores ≥7, and had metastases.
CONCLUSIONS: GCC is a unique subtype of gestational trophoblastic neoplasia, which differs from others in terms of poor prognosis, a frequent tendency to early metastasis, and resistance to treatment. To be able to achieve the most efficient therapy and prognosis, histopathology-based risk models should be developed.
摘要：
目的：探讨临床病理特征，预后因素，治疗,临床反应，和妊娠绒毛膜癌（GCC）的结局。
方法：对1992年至2020年在土耳其两个转诊中心诊断并治疗GCC的13例患者的临床病理和生存数据进行了回顾性回顾。
结果：患者的中位年龄为36岁（范围，27-54岁），七个≤39岁。9例（69.2％）的先期妊娠是一个术语，风险评分≥7/11(84.6%)。根据国际妇产科联合会2009年分期,八个病例处于第一阶段，第二阶段是第三阶段，第三阶段。除了一个病人,所有其他人都接受了联合化疗(CT)，其中两人也接受了放射治疗。化学抗性在50%(6/12)发展，其中4例接受了二线CT检查。总体完全缓解率为69.2%。四名患者死于化疗耐药和疾病进展，他们都是先期怀孕，高分≥7分，并有转移。
结论：GCC是妊娠滋养细胞肿瘤的一种独特亚型，在预后不良方面与其他人不同，早期转移的频繁趋势，和对治疗的抵抗力。为了能够达到最有效的治疗和预后，应开发基于组织病理学的风险模型。
方法：对1992年至2020年在土耳其两个转诊中心诊断并治疗GCC的13例患者的临床病理和生存数据进行了回顾性回顾。
结果：患者的中位年龄为36岁（范围，
结论：GCC是妊娠滋养细胞肿瘤的一种独特亚型，
